Bufalin engages in RIP1-dependent and ROS-dependent programmed necroptosis in breast cancer cells by targeting the...

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Breast cancer remains a leading cause of mortality in women globally.
• Bufalin exhibits anticancer properties, but its precise mechanism of cytotoxicity is not fully understood.
• Investigating novel cell death pathways is crucial for developing effective breast cancer therapies.

Purpose of the Study:

• To elucidate the mechanism by which bufalin induces cytotoxicity in breast cancer cells.
• To determine if bufalin triggers programmed necrosis (necroptosis) and identify the molecular pathways involved.
• To explore the potential of bufalin as a therapeutic agent targeting specific cell death pathways in breast cancer.

Main Methods:

• Cytotoxicity was assessed using MTT assays.
• Flow cytometry was employed to measure reactive oxygen species (ROS) production and cell death modes.
• Cellular morphology was examined via Hoechst 33342 and propidium iodide staining, alongside transmission electron microscopy.
• Western blotting was utilized to analyze protein expression, focusing on the RIPK1/RIPK3/PGAM5 pathway.

Main Results:

• Bufalin significantly reduced breast cancer cell viability.
• Bufalin treatment led to increased intracellular ROS production, which was reversible with Nec-1 and N-acetylcysteine.
• Morphological and molecular analyses confirmed the induction of necroptosis.
• Western blot results indicated bufalin upregulates RIPK1 and activates the RIPK1/RIPK3/PGAM5 pathway.

Conclusions:

• Bufalin effectively induces necroptosis in breast cancer cells.
• The RIPK1/RIPK3/PGAM5 pathway is a key mediator of bufalin-induced necroptosis.
• These findings highlight bufalin's potential as a novel therapeutic strategy for breast cancer by targeting necroptosis.